National advisory panels for paediatric cancer in the UK as an example of rare cancer multidisciplinary team meetings.

Abstract

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). We recognise the proposed advantages of multidisciplinary team (MDT) working that Rosell et al.1 describe in their evaluation paper. In the UK, multidisciplinary team (MDT) working is mandated in the National Health Service (NHS) Cancer Plan. Benefits of this model include improved evidence-based treatment decisions, coordination of care and education for MDT members, along with improved patient outcomes and clinical trial recruitment.2–5 Childhood cancer is rare. There are approximately 1900 new cases per year in the UK, with childhood cancer cases comprising less than 1% of all new cancer cases.6 All children with suspected cancer in the UK are referred to one of 19 principle treatment centres (PTC) which together comprise a network of tertiary specialist cancer services for diagnosis, treatment and coordination of care for each patient. It is standard of care for every child with a new diagnosis to be discussed at a PTC MDT meeting at which recommendations are formulated for management. In addition to PTC MDT meetings, there has been a recent rise in a number of virtual national advisory panels (NAP) for children’s cancer in the UK. These panels have developed alongside increasing centralisation of cancer services and enhanced complexities of patient management. Advice may be sought from these panels for individual patients with specific disease types including sarcoma (panel established in 2011), histiocytosis (2013), ependymoma (2015) leukaemia (2016), neuroblastoma (2017) and renal cancers (2017) As of January 2019, collectively there had been 920 referrals to the NAPs in the UK. Rosell et al. acknowledge rare cancers and complex cases may benefit from referrals to such forums to gather further clinical expertise, particularly when the evidence base is lacking or treatment pathway is not clearly defined. In contrast to the Swedish model described in Rosell’s evaluation, NAP referral is not mandated at either diagnosis or relapse. Furthermore, NAPs are distinct from PTC MDT meetings, involving national experts for particular cancer types offering an advisory role only ensuring overall responsibility for the patient remains that of the referring team. While the primary role of the NAPs is not to ensure equitable access to treatment, there is a degree of overlap with the UK Experimental Cancer Medicine Network regional meetings (ECMC). These meetings are designed to discuss cases at time of relapse to ensure equitable access to clinical trials, irrespective of geography. In contrast to the NAPs, it is an expectation that all children with relapsed disease in the UK are referred for discussion at an ECMC meeting. The foundation of each NAP is the personal investment of the chairs and panel members. Mirroring the implementation of the national MDTs in Sweden, their development occurred independently in an ad hoc basis and has not involved formal commissioning or processes. There is currently no allocated time in job plans to prepare cases or to attend the meetings. In terms of panel membership, the NAPs all have allocated chairs and multi-disciplinary input from radiology, surgery, oncology, radiotherapy and pathology. However, similar to that described in the Swedish model, there is currently minimal representation from allied health care professionals in UK NAPs. All of the NAP chairs are paediatric oncologists/haematologists who take on the coordination role in addition to chairing. These chair National advisory panels for paediatric cancer in the UK as an example of rare cancer multidisciplinary team meetings